Daniel Schneider

Daniel Schneider

Auto-generated profile, based on publicly available information

Daniel Schneider

Royal Melbourne Hospital, Parkville, VIC, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
DCDaniel Clayton-Chubb
Daniel Clayton-Chubb
DSDaniel Schneider
Daniel Schneider
EFElliot Freeman
Elliot Freeman
WKWilliam Kemp
William Kemp
SRStuart Keith Roberts
Stuart Keith Roberts

11 May 2022 in Medical Journal of Australia
Verified
Journal Article
Closed access
DSDaniel Schneider
Daniel Schneider
MSMichael Swan
Michael Swan
SHSimon Hew
Simon Hew

27 August 2026 in Science
Verified
Journal Article
Closed access
JPJiyi Pang
Jiyi Pang
AAAysha H. Al-Ani
Aysha H. Al-Ani
KPKomal M. Patel
Komal M. Patel
YZYunzhuo Zhou
Yunzhuo Zhou
SYSamuel N. Young
Samuel N. Young
JMJames M. Murphy
James M. Murphy
Inflammatory bowel disease (IBD) is a chronic condition caused by altered cytokine signaling, maladaptive immunity, dysbiosis, and intestinal barrier dysfunction. Although current therapies aim to correct these imbalances to induce remission, most patients ultimately relapse, suggesting that key pathogenic mechanisms persist. Here, we identified aberrant epithelial cell death signaling as an underlying feature of IBD that arises in patients in remission and on advanced therapy. Mechanistically, nascent inflammation skewed epithelial cells into an M1-macrophage–like transcriptional state that promoted RIPK1-independent necroptotic signaling. This signaling then triggered inducible nitric oxide synthase–assisted mitochondrial apoptosis of absorptive epithelial cells and PUMA-mediated intestinal stem cell death. Thus, aberrant epithelial cell death signaling represents a hallmark of IBD that occurs early in mucosal lesion development, persists despite current therapeutic strategies, and predicts clinical relapse.